Anagenics Poised to Gain from Antibody Licensing Deal

Anagenics Limited (AU:AN1) has released an update.

Anagenics Limited is set to benefit from a licensing deal involving its midkine intellectual property portfolio, with Roquefort Therapeutics signing a term sheet for the out-licensing of a midkine antibody portfolio to PDC FZ-LLC. The deal promises Anagenics a 4% royalty on net sales and an 8% royalty on net sublicensing revenue. Roquefort’s deal includes an initial consideration of $10M and potential trade sale proceeds, with definitive licensing agreements and further updates to follow.

For further insights into AU:AN1 stock, check out TipRanks’ Stock Analysis page.